-
Report: Biosimilars could save $20 billion per year
While the Food and Drug Administration released draft guidance on regulations for biosimilars in February 2012, the final regulations have yet to appear. But already, everyone from analysts to trade groups to drug makers is preparing for a time when knock-off versions of biotech drugs will become available.
A new report sheds light on some of the opportunities and challenges that exist in follow-on biologics, arguing that their opportunity to generate value depends on factors like the speed of development, clarity of regulation, ease of access and the roles of all stakeholders.
-
The DSN digital evolution
Like just about everybody else with a pulse these days, the coolest thing I own is my iPad. I know. How original — me and 53 million other people.
But there's a reason for that. The iPad reinvents the boring old way we used to do so many things, from how we shop to how we consume media. It is no surprise that iPad users spend twice as much as any other online customer. It's just so damn easy and cool, and well, fun.